Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aker BioMarine ASA's earnings before interest and taxes (EBIT) for the
six
months ended in Jun. 2026 was kr64 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was kr129 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Aker BioMarine ASA's annualizedROC % for the quarter that ended in Jun. 2026 was 3.94%.
Aker BioMarine ASA's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 6.98%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Aker BioMarine ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 1.14%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aker BioMarine ASA EBIT Related Terms
Aker BioMarine ASA EBIT Historical Data
* Premium members only.
The historical data trend for Aker BioMarine ASA's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Aker BioMarine ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aker BioMarine ASA EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Aker BioMarine ASA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aker BioMarine ASA's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr129 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aker BioMarine ASA (OSL:AKBM) has a EBIT of kr129 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aker BioMarine ASA.
Is Aker BioMarine ASA's EBIT too high?
Aker BioMarine ASA's current EBIT is kr129 Mil. Overall, Aker BioMarine ASA has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aker BioMarine ASA's EBIT compare to KHC and GIS?
Aker BioMarine ASA's EBIT of kr129 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aker BioMarine ASA. Aker BioMarine ASA's current EBIT is kr129 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aker BioMarine ASA stock overvalued right now?
Based on GuruFocus' analysis, Aker BioMarine ASA (OSL:AKBM) is currently considered Significantly Overvalued. The stock's GF Value™ is kr74.55, compared to a current price of kr109.00 — trading 46.2% above its estimated fair value. The current EBIT is kr129 Mil. Aker BioMarine ASA's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Aker BioMarine ASA (OSL:AKBM), the current EBIT is kr129 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aker BioMarine ASA (OSL:AKBM) Overvalued in 2026?
Based on GuruFocus' analysis, Aker BioMarine ASA stock appears to be overvalued.
The current stock price of kr109.00 is trading 46.2% above its estimated GF Value™ of kr74.55.
GuruFocus considers Aker BioMarine ASA to be Significantly Overvalued.
Key valuation signals for OSL:AKBM:
EBIT: kr129 Mil
GF Value™: kr74.55 vs. price of kr109.00 (46.2% above fair value)
No single metric tells the full story. See the OSL:AKBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include Human Health Ingredients, Consumer Health Products, and Emerging Businesses. The company generates the majority of its revenue from the Human Health Ingredients segment, which includes Superba, Lysoveta, PL+ Algae, and the company's Houston manufacturing plant. The segment sells B2B krill oil supplements to nutritional brands for humans around the world.
64GF Score
Get the complete analysis for OSL:AKBM
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:AKBM has been successfully added to your 
